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Abstract Calcific aortic valve disease (CAVD) results in
aortic valve stenosis and is one of the most common cardiac
diseases in both Western and developing countries. The bur-
denofthisdisease isexpectedtoincreaserapidly inthe future,
but there are still no relevant pharmacological therapies avail-
able and aortic valve replacement remains the sole definite
therapy. This review presents an overview of the most com-
mon causes of CAVD, followed by current debates and trials
related to the onset and progression of this disease. Several
differences and similarities between the different causes of
CAVD are presented. Additionally, stages of CAVD are com-
pared with stages in atherosclerosis. Finally, future directions
for research on CAVD will be discussed.
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Introduction
Calcific aortic valve disease (CAVD) is the most frequent
native valve disease in Europe (43.1%) followed by mitral
regurgitation (31.5%), aortic regurgitation (13.3%) and mi-
tral stenosis (12.1%) [1]. Aortic valve stenosis (AS) is
thought to represent the late stage of the pathological pro-
cess of CAVD, following aortic valve sclerosis, i.e. thicken-
ing of the aortic valve cusp without obstruction of the left
ventricular outflow (Fig. 1). Sclerotic and stenotic aortic
valves are characterised by a chronic inflammatory cell
infiltrate, which consists mostly of macrophages and T-
lymphocytes, accumulation of lipids, thickening and fibrosis
and eventual mineralisation [2]. The prevalence of aortic
valve sclerosis is 29% in the overall population, and up to
37% in those older than 75 years [3]. Estimates of patients in
whom sclerosis develops into AS ranges from 15–30%
within 6 to 8 years [4]. Approximately 2–3% of the popu-
lation of 65 years and older have been estimated to have AS
[3]. Life expectancy in patients with AS is severely reduced,
as indicated by Otto et al., who found that the probability to
be alive after two years for asymptomatic patients with a
peak jet velocity of>4 m/s and without aortic valve replace-
ment was only 21±18% [5].
Grossly, the most common aetiologies for CAVD are
degenerative, rheumatic and congenital (81.9%, 11.2% and
5.4% of the patients respectively) [1]. Despite several pro-
spective clinical trials, there are no effective pharmacologi-
cal therapies available for CAVD and the only effective
treatment is valve replacement. Several procedures are
available for aortic valve replacement, which include con-
ventional replacement surgery with biological or synthetic
prostheses and less invasive trans-apical or trans-femoral
therapies. Surgical treatment options for end-stage aortic
stenosis will not be discussed any further in this review.
In this review, we will provide an overview of the three
most common aetiologies and pathogeneses of CAVD and
present some of the latest concepts and results in clinical
trials aiming to prevent CAVD.
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The most frequent cause of CAVD is degenerative valve
disease and several risk factors have been correlated to the
progression this condition. The prospective Cardiovascular
Health Study correlated age, male gender, hypertension, ele-
vated levels of lipoprotein (a) and low-density lipoprotein
cholesterol (LDL), and smoking with the presence of aortic
valve sclerosis and stenosis [3]. Others also identified these
risk factors, in addition to diabetes and elevated body mass
index, the metabolic syndrome and end-stage renal disease,
amongst others [6]. Risk factors for degenerative CAVD are
thus suggested to be similar to the traditional risk factors for
atherosclerosis, which also include increasing age, male gen-
der, hypertension, diabetes, triglycerides, and smoking [3, 7]
and it has been hypothesised that acquired valve disease is a
manifestation of atherosclerosis. However, an inconsistency
has been found in the coexisting prevalence between CAVD
and coronary artery disease (CAD) as only 50% of patients
with severe CAVD have significant CAD, and the majority of
patients with CAD do not have CAVD [8]. This shows that
risk factors may be similar, but that there are also notable
differences between atherosclerosis and CAVD.
Pathogenesis of degenerative CAVD
Injury and activation of the valve endothelium by mechan-
ical forces, such as shear stress and transvalvular pressure, is
thought to be causative for the onset of CAVD [9]. Similar
to atherosclerosis, endothelial damage might initiate a num-
ber of events such as accumulation of lipoproteins and
inflammation [2, 10]. Several adhesion molecules, which
are normally not expressed by the valvular endothelium,
are found in non-rheumatic aortic valve disease. Monocytes
can adhere to these adhesion molecules and migrate into the
subendothelial space [10], where they release cytokines,
chemokines, growth factors and proteolytic enzymes. In
addition, ApoA and ApoB have been found to accumulate
in developing lesions of CAVD. Oxidative modifications
make these lipoproteins highly cytotoxic for most cells and
the products generated by lipid oxidation have shown pro-
inflammatory properties. It is likely that inflammation and
lipid oxidation cause activation and differentiation of the
valve interstitial cells (VICs), which are responsible for the
maintenance and repair of the valve matrix structure.
In pathological processes, inflammatory cells are the
main source of matrix-metallo proteinases (MMPs).
Tenascin-C (TN-C) is an extra-cellular matrix glycoprotein,
which is often co-expressed with MMPs, and is overex-
pressed by interstitial myofibroblasts in aortic valve calcifi-
cation. TN-C actively participates in physiological bone
formation and stimulates osteoblastic differentiation [11].
During progression of aortic valve sclerosis to CAVD, pos-
itive feedback mechanisms between MMP-2 and TN-C lead
to increased alkaline phosphatase expression, which is a
crucial enzyme for bone formation and bone cell differenti-
ation, and deposition of calcium phosphates [12]. MMP
activity has also been identified as an activator of trans-
forming growth factor-beta 1 (TGF-β1) [13], which is over-
expressed in stenotic valves [14] and has been suggested to
play an active role in progression of the disease [15].
Macrophages have also been found to express angiotensin-
converting enzyme (ACE) in atherosclerosis. In valvular tis-
sue, local production of ACE has been demonstrated [16].
Enzymatically active ACE was also found to be present in
aortic sclerosis and CAVD lesions, where it might participate
in disease progress with local production of angiotensin II
[17]. Angiotensin II is an important mediator of inflammation
and fibrosis and therefore a potential initiator of processes
involved in CAVD progression [18].
Lastly, it has been suggested that VIC differentiation
towards osteoblasts in valvular calcification is enhanced
by the osteoprotegerin (OPG)/receptor activator of nuclear
factor-κB (RANK)/RANK ligand (RANKL) system.
RANKL expression was increased, while OPG was de-
creased in human calcified aortic valves [19]. In cultured
VICs, RANKL stimulation leads to the induction of an
osteogenic phenotype, a significant rise in matrix calcifica-
tion, alkaline phosphatase activity, expression of osteocalcin,
Fig. 1 Echographic images showing the aortic valve in different stages
of the disease: normal (a), sclerotic (b, early stage, low transvalvular
gradient) and stenotic (c, end stage). All images were obtained using
short-axis TEE in the same angle. NC: Non-coronary cusp, L: Left
coronary cusp, R: Right coronary cusp. Arrow marks improper closing
of the severely stenotic valve causing a valvular leak
Neth Heart J (2012) 20:270–278 271and increased functioning of the transcription factor Runx2,
which is essential for onset of genes involved in osteogenic
differentiation.
Together, these data provide a brief overview of the possi-
ble processes involved in risk factors, onset, progression and
end-stage differentiation in degenerative CAVD, while addi-
tionalpathwayshavebeenreviewedbyothers[6].Riskfactors
similar to atherosclerosis, combined with high continuous me-
chanical stress, are thus most likely important for onset of
CAVD, followed by inflammatory processes and gradual oste-
ogenic differentiation with AS as the end-stage (Fig. 2a and b).
Congenital aortic valve disease
Congenital aortic valve disease includes unicuspid, bicus-
pid, quadricuspid and even pentacuspid valves. Bicuspid
aortic valve (BAV) is the most common congenital cardiac
abnormality, occurring in about 1–2% of the population,
with a higher prevalence in males [20]. Unicuspid aortic
valves, which is the second most common congenital valve
disease, occurs in 0.02% of the population. In this review,
the focus will be on BAVs.
BAV is the second most common cause of CAVD and is
the result of abnormal aortic cusp formation during a com-
plex developmental process. From a recently suggested
classification system, it can be extracted that there are several
types of BAVs, with different incidences [21]. It showed that
only few patients congenitally have two commissures and no
raphe (type 0: 7%) and that the majority have conjoined or
fused cusps resulting in one (type 1: 88%) or more (type 2:
5%) raphes. Moreover, there seems to be a genetic predispo-
sition for the location of the raphe in the type 1 BAVs, as
suggested by the high incidence of fusion of the left and right
coronary cusp (71%) and the low incidence of fusion of the
left and non-coronary cusp (3%) [21]. Although the informa-
tion on the effect of these different types of BAVs on calcifi-
cationisnotyetknown,thereare indicationsthatCAVDtends
to progress more rapidly if the cusps are asymmetrical and in
an anteroposterior position [20]. Patients with BAVare gener-
ally 10 years younger than those with tricuspid CAVD when
requiring aortic valve replacement. It is likely that the pro-
gressionofCAVDinthesepatientsissimilartothatinpatients
with tricuspid valve degenerative calcification [22], but that
the process starts earlier in life due to higher mechanical
stresses on the cusps and more turbulent blood flow due to
abnormal configuration of the cusps [23].
Pathogenesis of BAV
It has been suggested that onset of CAVD in BAVs is the
result from less natural folding, incomplete opening and
Fig. 2 a Stenotic tricuspid
valve, prior to replacement. b
Excised cusps of stenotic tricus-
pid valve, showing large calcific
nodules in the tissue, primarily
located at the belly region of the
valve. c Stenotic congenital
bicuspid valve, prior to replace-
ment. d Excised cusps of ste-
notic congenital bicsupid valve,
also showing large calcified
deposition in the belly region of
the cusp. e Explanted aortic
valve after rheumatic aortic
valve disease, obtained from
Robins and Cotran, Pathologic
Basis of Disease, 7th edition,
Elsevier Health Sciences. This
shows thickening of the cusps
and fusion of the commissures
following healing and scarring
after the acute phase of
the disease
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cycle, making it more prone to tissue damage as compared
with tricuspid valves [24]. The increased turbulence in the
blood flow causes trembling and whipping of the cusps, pre-
disposing them to fibrosis and calcification [24]. In addition,
recent modelling studies noted that the orifice area of BAVs,
functioning normally on echocardiography, may already re-
semble valves with some degree of stenosis [25]. The over-
loaded stresses revealed by the model may accelerate
degeneration as described for degenerative valve disease
[25]. The models do not explain why aortic valves become
bicuspid in the first place, but this has been correlated with
mutations in Notch signalling. Notch is a receptor which has
been attributed several important roles in embryonic develop-
ment, but that is also linked to endothelial functioning and
suppression of osteogenic transcription factor Runx2. Hence,
mutations in Notch could be causative for accelerated pro-
gression of valve calcification as well [6]. Lastly, recent dis-
coveries have identified altered expression of microRNAs
(miRs) 26a, 30b and 195 in calcific and non-calcific regurgi-
tant BAVs [26]. MiRs are small sequences of nucleotides that
can influence protein expression and they may provide targets
for future therapies as has been shown in several in vivo
studies [27].
In summary, progression of calcification in BAVappears
to have many similarities with degenerative CAVD in tri-
cuspid valves, although it most likely progresses faster due
to higher mechanical stresses on the cusp. A severely ste-
notic congenital bicuspid valve is presented in Fig. 2c and d.
Rheumatic aortic valve disease
Although the incidence of rheumatic aortic valve disease has
declined in industrialised countries, it is estimated that
worldwide nearly 20 million people are affected by acute
rheumatic fever and rheumatic heart disease, of which 95%
in developing countries. The first step in the pathogenesis of
rheumatic valve calcification is pharyngitis due to Strepto-
coccus pyogenes, or group A streptococci (GAS), but only
0.3–3% of individuals with acute GAS pharyngitis go on to
develop rheumatic fever [28]. Despite a significant decline
in the incidence of acute rheumatic fever in developed
countries there has been no apparent decline in GAS phar-
yngitis [28]. This may be explained by the rapid and appro-
priate diagnosis, and antibiotic management of even
uncomplicated GAS infections, or the occurrence of less
virulent serotypes becoming more dominant with time.
Each year there are 470,000 incident cases of rheumatic
fever worldwide and 233,000 deaths due to acute rheumatic
fever and rheumatic heart disease [29]. The mean annual
incidence rates are lowest in American and Western Euro-
pean countries and relatively a bit higher in Eastern Europe,
Asia, Australasia, and the Middle East. The highest reported
mean annular incidences were found in India and in a Maori
community in New Zealand [30]. However,theprevalencein
African countries such as Kenya and Congo has been estimat-
ed to be a lot higher [28]. Even these estimates have been
suggested to be underestimations, since more systematic
screening with echocardiography resulted in even higher
numbers in other developing countries, such as Cambodia
and Mozambique [31]. (Fig. 3)
Pathogenesis of rheumatic valve disease
The cytoplasmic membrane of GAS contains several pro-
teins and groups that are highly similar to proteins found in
the human host. This results in molecular mimicry, or the
sharing of epitopes between antigens of the host and the
bacteria, and may stimulate existing B and Tcells to respond
to self proteins [32]. Rheumatic heart disease can be a
serious autoimmune consequence of acute rheumatic fever.
For example, the sites where anti-streptococcal/anti-myosin
antibodies bind to valvular endothelium may serve as infil-
tration sites for activated T cells and macrophages [32, 33].
Inside the inflammatory infiltrate, cells produce valve in-
flammation, scarring and destruction of valvular tissue. The
valve turns into a local microenvironment for continuous
cytokine production, lymphocyte infiltration, inflammation,
and scarring [33]. Infiltrated lymphocytes and macrophages
allow for the formation of so-called Aschoff bodies in the
valve. Aschoff bodies are characteristic lesions of rheumatic
heart disease, consisting of granulomatous structures with
fibrinoid change and chronic inflammation of the valve
Fig. 3 Graphic presentation of measured or estimated incidence of
rheumatic aortic valve disease in Western and developing countries
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previously avascular valve tissue will lead to irreversible
deformation of the valve (Fig. 2e)[ 32, 33]. Concomitant
identification of osteopontin, osteocalcin, periostin and
increased bonematrixproteinsynthesissuggeststhatasimilar
osteoblast-like phenotype is involved in rheumatic valves as
well as in degenerative CAVD [34].
Pharmacological treatment
In search for effective pharmacological treatment of CAVD,
the discussion has often focused on similarities between
CAVD and atherosclerosis [35], although contradictory
studies have also been published [6, 36]. Currently, the
debate seems to shift back to focusing on the differences
between the two conditions. Atherosclerotic lesions gener-
ally consist of foam cells that fuse to form lipid accumula-
tions surrounded by fibrous caps, while early valvular
lesions have been suggested to lack foam cells and progress
to mineralised matrix and in some cases bone structures [6].
However, lipid accumulations are also observed in minimal-
ly sclerotic valves derived from explanted hearts for trans-
plantation [2] and mature lamellar bone formation has also
occasionally been described in atherosclerotic lesions
(Fig. 4)[ 37]. These data show that both atherosclerosis
and CAVD may occur in several manifestations, but that
most manifestations of atherosclerotic lesions also occur in
valves and vice versa. Thus, in many cases, risk factors and
causes of atherosclerotic and valvular lesions may be simi-
lar, but different mechanic environments and cells involved
may cause slightly different progressions and end-stages of
the diseases. These small differences might explain why
therapies used to slow progression of atherosclerosis are
not always successful for inhibition of CAVD progression.
One of the key factors in the pathogenesis of CAVD
appears to be lipoproteins. The lipid-lowering agents
HMG-CoA reductase inhibitors (statins) are used to lower
cholesterol levels, exert significant anti-inflammatory
effects and also preserve endothelial function in atheroscle-
rotic disease. Several studies have been published in which
serum cholesterol levels were lowered and calcium accumu-
lation or inflammation in the valve were reduced, resulting
in inhibited progression of CAVD [38]. However, these
studies were predominantly retrospective or had small sam-
ple sizes. Three recent prospective randomised double-blind
studies revealed that statin treatment did not have any effect
on the progression of CAVD. According to the Scottish
Aortic Stenosis and Lipid Lowering Trial, Impact on Regres-
sion (SALTIRE) study [39] high-dose statin therapy does not
halt the progression of CAVD over a 2-year follow-up period,
despite reducing the LDL cholesterol by more than 50%.
Similar results were found in the Simvastatin and Ezetimibe
in Aortic Stenosis (SEAS) trial [40], during a median
follow-up of at least 4 years. An average reduction in
LDL cholesterol of at least 50% was found in addition
to reduced incidence of ischaemic cardiovascular events,
but no changes in CAVD progression. The third pro-
spective trial, Aortic Stenosis Progression Observation:
Measuring Effect of Rosuvastatin (ASTRONOMER)
[41], included patients who were nearly 10 years youn-
ger than in the SALTIRE and SEAS trials, to better
represent the population suffering from CAVD (58 years
on average). There was a 54.5% reduction in LDL concen-
tration, but no reduction of progression of CAVD. The results
of studies are consistent in demonstrating that lipid lowering
does not affect CAVD progression in patients with no clinical
indications for lipid lowering.
Preliminary observational studies with ACE inhibitors
(ACEi) have produced conflicting results. Rosenhek et al.
[42] found that progression of CAVD was not significantly
delayed in patients using ACEi. In contrast, a small retro-
spective study found an association between ACEi use and
lower rate of aortic valve calcium accumulation [43]. More
recent investigations showed that angiotensin receptor 1
blockers inhibited atherosclerotic changes and endothelial
disruption in aortic valves [44]. More research may reveal
new targets for therapies in this pathway.
Recent observational studies observed that patients receiv-
ing treatment for osteoporosis, especially bisphosphonates,
had significantly less calcium deposition in the aortic valve
and a slower progression of degenerative CAVD [41, 45]. In
addition, members from our group have shown that valvular
calcification correlates strongly to osteoporotic remodelling
[46]. Lastly, a recent trial has shown that bisphosphonates can
reduce cardiovascular calcification in patients >65 years, but
thatithadnoeffectinyoungerpatients[47].Thismayindicate
that there are different stages in the progression of CAVD, in
which recruitment of calcium is the last stage, and that
bisphosphonates may be beneficial in inhibiting the progres-
sion of this last stage only.
For all the therapies described, both successful and unsuc-
cessful results on progression of CAVD have been reported,
but better matching of different stages of CAVD with specif-
ically applied therapies may shift the balance towards more
effective treatment.
Future directions
The previous sections show that there are no therapies
available directed specifically against pathological process-
es in aortic valve disease. Instead, several experiments have
been conducted with pharmacological agents that were suc-
cessful against other cardiovascular diseases that resemble
aspects of CAVD and were therefore thought to be
274 Neth Heart J (2012) 20:270–278promising for inhibition of CAVD as well. Limitations pre-
venting successful development of pharmacological thera-
pies for CAVD are the lack of suitable animal models,
insufficient understanding of processes behind progression
of the disease and most important: lack of knowledge on
normal valve regeneration. VICs are able to actively main-
tain and repair the matrix structure of the valve, but it
remains unknown which triggers are responsible for the
Fig. 4 Atherosclerosis versus degenerative aortic valve disease. a, c, e
and g. Atherosclerosis. a Coronary artery vessel wall with an early
atherosclerotic lesion (fatty streak). Adv0adventitia; Med0media and
Fs0fatty streak. Bar0150 μm. c Higher magnification of A showing
foamy macrophages in the intima. Bar050 μm. e Advanced athero-
sclerotic lesion in the aorta. Bar0300 μm. g higher magnification of E
showing bone formation in the atherosclerotic lesion. Foamy macro-
phages are present in between the bone fragments. Bar0100 μm. b, d,
f, h. Degenerative aortic valve disease. b Cross section through aortic
valve leaflet showing the three layer structure with early lesions. Bar0
250 μm. d higher magnification of B showing foamy macrophages and
cholesterol clefts in the lamina fibrosa of the valve leaflet. Bar0
100 μm. f Advanced degenerative lesion with bone formation in aortic
valve. Bar0400 μm. h Higher magnification of F showing blood-
forming bone marrow next to the bone fragments in the aortic valve
leaflet. Bar0125 μm
Neth Heart J (2012) 20:270–278 275activation of these regenerative capacities and more impor-
tantly, what causes it to get out of control and thereby
initiate fibrosis and sclerosis in the cusps. For this purpose,
itisimportantthatinvitroandinvivomodelsaredevelopedin
which the processes that are specific for CAVD can be iden-
tified and targeted with newly developed therapeutic agents.
An example of these therapeutic agents could be modi-
fied small nucleotide chains called antagomirs, which can
target specific miRs in vivo [48]. MiRs are known to be
involved in processes such as angiogenesis and fibrosis and
the first pre-clinical trials indicate that specific miRs can be
successfully targeted to prevent or stimulate these events
[49, 50]. The first investigations in BAVs reveal that there is
also altered miR expression in calcified and non-calcified
valves [21] and further investigations may reveal additional
miRs, proteins and pathways involved in CAVD.
However, it should be noticed that successful develop-
ment of pharmacological therapies that slow down progres-
sion of CAVD will not suffice to prevent surgery in most
patients. Currently, most patients are diagnosed with CAVD
when they have become symptomatic and at this stage, it
may be too late for pharmacological intervention. Therefore,
it is important that the search for medication is combined with
additional genetic research in humans in order to identify
patients at risk before CAVD is initiated. As described above,
researchers have been able to identify several potentially
interesting genes that may cause BAVs in mice, but these
models cannot be translated to humans yet [6] and there is
not much known about genetic predisposition for CAVD.
Summary
The pathogenesis of non-rheumatic aortic valve calcification
is probably initiated by damage to the endothelial layer
overlying the valve, followed by accumulation of low-
density lipoprotein and infiltration of inflammatory cells.
Oxidative stress, release of inflammatory cytokines and
growth factors, and extracellular matrix remodelling create
an environment that facilitates the proliferation and osteo-
blastic differentiation of VICs, which ultimately leads to
calcification and occasionally ossification of the aortic
valve. In BAV, calcification is likely to occur earlier than
in patients with a tricuspid aortic valve, as altered mechan-
ical stress accelerates valvular trauma. The processes fol-
lowing valvular trauma are probably similar in tricuspid and
bicuspid valves. Rheumatic valve disease is initiated by
inflammation, caused by pharyngitis due to GAS followed
by the release of cytokines, activation of VICs, matrix
remodelling and eventually osteogenic differentiation of
VICs. These processes and the discovery of osteopontin,
osteocalcin, and increased bone matrix protein synthesis in
rheumatic aortic valves suggest that a similar osteoblast-like
phenotype is involved in rheumatic valve disease as that in
Fig. 5 Overview of possible disease pathways as discussed and pre-
sented in this review. Degenerative CAVD and bicuspid CAVD are
likely to follow a similar pathway, but the higher mechanical stress
may induce the process early on. Genetical causes for bicuspid CAVD
have not yet been identified, but cannot be ruled out yet. Rheumatic
CAVD is caused by specific bacterial infections, but following healing
and scarring (dashed/solid arrows), these valves also calcify and inter-
stitial cells have been found to undergo osteogenic differentiation. The
dashed arrow between matrix remodelling and calcification shows that
this process may occur, but for severely stenotic valves, the path
through osteogenic differentiation is probably more likely. The sug-
gested therapies so far have not been successful in stopping progres-
sion of CAVD. Statins and inhibitors of ACE-related processes have
been suggested to be primarily involved in prevention of onset of
CAVD, while bisphosphonates were reported to be beneficial at later
stages of the disease. For all therapies, both successful and unsuccess-
ful results on progression of CAVD have been reported. Better match-
ing of different stages of CAVD with specific applied therapies may
shift the balance towards more effective treatment
276 Neth Heart J (2012) 20:270–278non-rheumatic CAVD. The three forms of CAVD, including
currently debated pharmacological treatments, are depicted
in Fig. 5. In conclusion, current evidence suggests that there
are differences in the onset of several types of CAVD, but
that there are similarities in the progression of the disease,
which is interesting for development of pharmacological
treatments in the future.
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